Head & Neck Cancer

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

The combination of lirilumab Opdivo proved to be effective for a subet of patients with head and neck cancer, according to a recent study.

Everett Vokes, M.D. discusses what the future of immunotherapy might mean for patients with head and neck cancer.

Opdivo was approved for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

In an interview with CURE, James Allison, Ph.D. talks about the progress immunotherapy has made, as well as potential combinations with immunotherapy and other treatment types to provide better outcomes for patients.

The addition of immunotherapy did not show an improved progression-free survival for some patients with head and neck cancer.

The approval of Keytruda for metastatic head and neck squamous cell carcinoma is just the beginning when it comes to treating head and neck cancer with immunotherapy.

An accelerated FDA approval has been granted to the immunotherapy Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-containing chemotherapy.

Two trials testing Gilotrif's efficacy in head and neck cancer were stopped after a panel decided it was unlikely the drug would prove beneficial.

Elderly patients with head and neck cancer will now be able to get more individualized treatment plans, thanks to advances in the field, Sandro V. Porceddu says.

The need for new treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is dire, says Ranee Mehra.

Survivors of head and neck cancer often face unique challenges, and physical therapy can help.

Keytruda is showing promise for difficult-to-treat forms of head and neck cancer, according to two studies.

According to results from a phase 3 study, Opdivo improved overall survival and objective response rates for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Immunotherapy is showing promise for treatment of head and neck cancer who progress after chemotherapy, though there is still a long way to go, says Robert Ferris.

A team approach to treatment could improve outcomes for patients with head and neck cancer.

Being covered in cat fur feels wonderful.

The FDA granted Opdivo (nivolumab) a breakthrough therapy designation to treat certain patients with head and neck cancer.

A phase 3 study presented at the 2016 AACR Annual Meeting showed that Opdivo doubled one-year survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma.

A priority review designation was granted to Keytruda for some patients with head and neck cancer. A decision submission is due in August.

As the number of HNC survivors continues to increase, the American Cancer Society issued new guidelines for patients and their physicians.

Sometimes rational thinking isn't my strong suit.